OLMA Key Statistics, Chart & Performance
The current stock price of OLMA is 24.57 USD. In the past month the price decreased by -4.17%. In the past year, price increased by 302.13%.
OLMA Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to OLMA. When comparing the yearly performance of all stocks, OLMA is one of the better performing stocks in the market, outperforming 99.16% of all stocks.
OLMA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to OLMA. OLMA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
OLMA Financial Highlights
Over the last trailing twelve months OLMA reported a non-GAAP Earnings per Share(EPS) of -1.87. The EPS increased by 14.61% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -42.55% | ||
| ROE | -48.77% | ||
| Debt/Equity | 0.01 |
OLMA Forecast & Estimates
15 analysts have analysed OLMA and the average price target is 45.9 USD. This implies a price increase of 86.81% is expected in the next year compared to the current price of 24.57.
OLMA Ownership
About OLMA
Company Profile
Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery, development, and commercialization of next generation targeted therapies for women’s cancers. The company is headquartered in San Francisco, California and currently employs 122 full-time employees. The company went IPO on 2020-11-19. The firm is focused on transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. The company is advancing a pipeline of novel therapies by leveraging its deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. Its lead product candidate, palazestrant (OP-1250), is a proprietary, orally available complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD), in a Phase 3 clinical trial called OPERA-01. The company is being investigated in patients with recurrent, locally advanced or metastatic ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. In addition, it is developing OP-3136, a potent KAT6 inhibitor, in a Phase 1 clinical trial. OP-3136 is a novel, orally available small molecule that potently and selectively inhibits KAT6.
Company Info
OLEMA PHARMACEUTICALS INC
780 Brannan Street
San Francisco CALIFORNIA 94107 US
CEO: Sean Bohen
Employees: 122
Phone: 14156513316
OLEMA PHARMACEUTICALS INC / OLMA FAQ
What does OLEMA PHARMACEUTICALS INC do?
Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery, development, and commercialization of next generation targeted therapies for women’s cancers. The company is headquartered in San Francisco, California and currently employs 122 full-time employees. The company went IPO on 2020-11-19. The firm is focused on transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. The company is advancing a pipeline of novel therapies by leveraging its deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. Its lead product candidate, palazestrant (OP-1250), is a proprietary, orally available complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD), in a Phase 3 clinical trial called OPERA-01. The company is being investigated in patients with recurrent, locally advanced or metastatic ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. In addition, it is developing OP-3136, a potent KAT6 inhibitor, in a Phase 1 clinical trial. OP-3136 is a novel, orally available small molecule that potently and selectively inhibits KAT6.
What is the stock price of OLEMA PHARMACEUTICALS INC today?
The current stock price of OLMA is 24.57 USD. The price decreased by -5.86% in the last trading session.
Does OLEMA PHARMACEUTICALS INC pay dividends?
OLMA does not pay a dividend.
What is the ChartMill technical and fundamental rating of OLMA stock?
OLMA has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the number of employees for OLEMA PHARMACEUTICALS INC?
OLEMA PHARMACEUTICALS INC (OLMA) currently has 122 employees.
What is the next earnings date for OLMA stock?
OLEMA PHARMACEUTICALS INC (OLMA) will report earnings on 2026-03-16, after the market close.